Healthcare / Medical DevicesStockholm
$1.07
-0.09 (-7.76%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-15.0M · quality 79.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$28M
P/E
15.3x
↓EV/EBITDA
5.3x
↓ROE
0.4%
↑Gross Margin
98.1%
↑Debt/Equity
0.22
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.1%
FCF CAGR
—
FCF margin
-53.9%
FCF / Net income
-70.15x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $27.9M · net income $214492.0 · FCF $-15.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $27.9M | $27.9M | $25.2M | $24.2M | $21.5M |
| Net Income | $214492.00 | $214492.00 | $-2.1M | $-5.6M | $-1.7M |
| EBITDA | $6.7M | $6.7M | $4.5M | $-852406.00 | $92897.00 |
| EPS | 0.01 | 0.01 | -0.23 | -0.62 | -0.11 |
| Gross Margin | 98.1% | 98.1% | 111.3% | 117.2% | 113.0% |
| Operating Margin | 7.6% | 7.6% | 0.5% | -17.0% | -3.6% |
| Net Margin | 0.8% | 0.8% | -8.3% | -23.1% | -8.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.22 | 0.22 | 0.69 | 0.52 | 1.09 |
| Current Ratio | 2.79 | 2.79 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-15.0M | $-15.0M | $-7.6M | $-15.3M | $-6.6M |
| Returns | |||||
| ROE | 0.4% | 0.4% | -7.3% | -18.3% | -10.7% |
| Valuation | |||||
| P/E | 15.29 | 15.29 | — | — | — |
| EV/EBITDA | 5.30 | 5.30 | 7.79 | — | 1417.32 |
| P/B | 0.49 | 0.49 | 0.56 | 0.97 | 7.02 |
| Growth & Yield | |||||
| Revenue Growth | 10.8% | 10.8% | 4.4% | 12.5% | — |
| EPS Growth | 103.5% | 103.5% | 62.7% | -463.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
126.4%
EPS terminal req.
$0.09
Spread vs growth
-22.9%
5Y implied EPS CAGR
69.6%
EPS terminal req.
$0.11
Spread vs growth
33.9%
10Y implied EPS CAGR
36.6%
EPS terminal req.
$0.19
Spread vs growth
66.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-57.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.23 → 0.01
Residual
-57.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.